JP2010180206A - Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof - Google Patents
Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof Download PDFInfo
- Publication number
- JP2010180206A JP2010180206A JP2010003318A JP2010003318A JP2010180206A JP 2010180206 A JP2010180206 A JP 2010180206A JP 2010003318 A JP2010003318 A JP 2010003318A JP 2010003318 A JP2010003318 A JP 2010003318A JP 2010180206 A JP2010180206 A JP 2010180206A
- Authority
- JP
- Japan
- Prior art keywords
- salt
- composition
- ascorbic acid
- diphenhydramine
- discoloration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 109
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 75
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 238000002845 discoloration Methods 0.000 title claims abstract description 42
- 229960000520 diphenhydramine Drugs 0.000 title claims abstract description 39
- 235000010323 ascorbic acid Nutrition 0.000 title claims abstract description 38
- 239000011668 ascorbic acid Substances 0.000 title claims abstract description 38
- 229960005070 ascorbic acid Drugs 0.000 title claims abstract description 38
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 title claims abstract 8
- 238000000034 method Methods 0.000 title claims description 21
- 230000002401 inhibitory effect Effects 0.000 title description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 37
- 239000002628 heparin derivative Substances 0.000 claims description 21
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 18
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 18
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 18
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 17
- 229920002674 hyaluronan Polymers 0.000 claims description 14
- 229960003160 hyaluronic acid Drugs 0.000 claims description 14
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 12
- 229940051593 dermatan sulfate Drugs 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 10
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 33
- -1 sucrose fatty acid ester Chemical class 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 206010013786 Dry skin Diseases 0.000 description 11
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000037336 dry skin Effects 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000013112 stability test Methods 0.000 description 9
- 201000004624 Dermatitis Diseases 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 7
- 229940014041 hyaluronate Drugs 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 4
- 235000010378 sodium ascorbate Nutrition 0.000 description 4
- 229960005055 sodium ascorbate Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PDMUULPVBYQBBK-UHFFFAOYSA-N 4-[(3-butoxy-4-methoxyphenyl)methyl]-2-imidazolidinone Chemical compound C1=C(OC)C(OCCCC)=CC(CC2NC(=O)NC2)=C1 PDMUULPVBYQBBK-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 206010048218 Xeroderma Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 230000001139 anti-pruritic effect Effects 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003822 epoxy resin Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 206010021198 ichthyosis Diseases 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229920000647 polyepoxide Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000037307 sensitive skin Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PDHAOJSHSJQANO-OWOJBTEDSA-N Oxyresveratrol Chemical compound OC1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 PDHAOJSHSJQANO-OWOJBTEDSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000012611 container material Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- DRGAZIDRYFYHIJ-UHFFFAOYSA-N 2,2':6',2''-terpyridine Chemical compound N1=CC=CC=C1C1=CC=CC(C=2N=CC=CC=2)=N1 DRGAZIDRYFYHIJ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- XDBMXUKHMOFBPJ-ZAFYKAAXSA-N L-ascorbic acid 2-sulfate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OS(O)(=O)=O)=C1O XDBMXUKHMOFBPJ-ZAFYKAAXSA-N 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004962 Polyamide-imide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000000474 heel Anatomy 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002312 polyamide-imide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001180 sulfating effect Effects 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する外用組成物の経時的な変色を抑制する方法に関する。 The present invention relates to a method for suppressing discoloration with time of an external composition containing diphenhydramine or a salt thereof and ascorbic acid or a salt thereof.
ジフェンヒドラミン又はその塩は、強い抗ヒスタミン作用を有することから、止痒・鎮痒効果を期待して、医薬品・医薬部外品の薬理活性成分として汎用されている。アスコルビン酸又はその塩は、抗炎症効果、ニキビ改善効果、美白効果、老化防止効果、抗酸化効果などを期待して、医薬品、医薬部外品、化粧品など幅広い用途に汎用されている。ところが、ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する製剤は、熱や光によって経時的に変色が生じる場合があることが知られている。このような変色が生じると商品価値が低下して好ましくないため、その解決手段もこれまでに検討されている。 Diphenhydramine or a salt thereof is widely used as a pharmacologically active ingredient in pharmaceuticals and quasi-drugs in anticipation of antipruritic and antipruritic effects since it has a strong antihistamine action. Ascorbic acid or a salt thereof is widely used in a wide range of applications such as pharmaceuticals, quasi-drugs, and cosmetics in anticipation of an anti-inflammatory effect, an acne improving effect, a whitening effect, an anti-aging effect, an antioxidant effect, and the like. However, it is known that a formulation containing diphenhydramine or a salt thereof and ascorbic acid or a salt thereof may be discolored over time due to heat or light. When such discoloration occurs, the commercial value is lowered, which is not preferable.
例えば、ジフェンヒドラミン又はその塩の熱による変色に対しては、ジフェンヒドラミン類を含有する油脂性軟膏剤に、ジブチルヒドロキシトルエンを単独で、又はジブチルヒドロキシトルエン及びメントールを組み合わせて添加することにより、当該油脂性軟膏剤の変色が防止できることが開示されている（特許文献１）。 For example, for heat discoloration of diphenhydramine or a salt thereof, by adding dibutylhydroxytoluene alone or in combination of dibutylhydroxytoluene and menthol to an oily ointment containing diphenhydramines, It is disclosed that discoloration of an ointment can be prevented (Patent Document 1).
さらに、ジフェンヒドラミン又はその塩の光による変色に対しては、ジフェンヒドラミン又はその塩を含有する製剤を遮光性を有する箱や包装容器内に保管する他、固形製剤の場合は、遮光剤を有するコーティング剤でジフェンヒドラミンを含有する製剤を被覆すること（特許文献２、３）、ジフェンヒドラミン塩を油液中に分散させる（特許文献４）、特定の高分子化合物（特許文献５：カルボキシメチルセルロースカルシウム、特許文献６：低膨潤性高分子及び高膨潤性高分子）を添加して製剤化するなどの手段により、ジフェンヒドラミン又はその塩を含有する製剤の変色が防止できることが開示されている。 Furthermore, for the discoloration of diphenhydramine or a salt thereof due to light, in addition to storing the preparation containing diphenhydramine or a salt thereof in a light-shielding box or packaging container, in the case of a solid preparation, a coating agent having a light-shielding agent Coating a formulation containing diphenhydramine (Patent Documents 2 and 3), dispersing a diphenhydramine salt in an oil liquid (Patent Document 4), a specific polymer compound (Patent Document 5: carboxymethylcellulose calcium, Patent Document 6) It is disclosed that discoloration of a preparation containing diphenhydramine or a salt thereof can be prevented by means such as adding a low-swelling polymer and a high-swelling polymer).
アスコルビン酸又はその塩の光による変色に対しては、ポリメタクロイルオキシエトキシホスホリルコリンと組み合わせて添加することにより、変色が防止できることが開示されている（特許文献７）。さらに、アスコルビン酸又はその塩の熱による変色に対しては、合成スチブンサイトと組み合わせて添加することにより、高温時の経時的な変色が抑えられることが開示されている（特許文献８）。 It is disclosed that discoloration due to light of ascorbic acid or a salt thereof can be prevented by adding in combination with polymethacryloyloxyethoxyphosphorylcholine (Patent Document 7). Furthermore, it is disclosed that, with respect to discoloration of ascorbic acid or its salt due to heat, discoloration over time at high temperatures can be suppressed by adding it in combination with synthetic stevensite (Patent Document 8).
また、アスコルビン酸又はその塩の経時的に変色する問題については、このアスコルビン酸又はその塩の変色に対して、オキシレスベラトロールと組み合わせてレシチンを用いてゲル化すること（特許文献９）、ショ糖脂肪酸エステルと組み合わせて多価アルコールを含有しない皮膚外用剤（特許文献１０）とすることで変色が防止できることが開示されている。 As for the problem of discoloration of ascorbic acid or its salt over time, gelling using lecithin in combination with oxyresveratrol for discoloration of this ascorbic acid or its salt (Patent Document 9), It is disclosed that discoloration can be prevented by combining with a sucrose fatty acid ester to obtain an external preparation for skin containing no polyhydric alcohol (Patent Document 10).
しかしながら、ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する製剤の、経時的な変色、特に熱及び／又は光による経時的な変色を抑制する手段としてムコ多糖類が有効であることはこれまでに知られていなかった。
さらに、特許文献１〜１０に開示された方法は、光又は熱の一方による変色を抑制するものであり、光及び熱の両方による変色に対して有効な方法もこれまでに知られていない。
However, it has been known that mucopolysaccharides have been effective as a means to suppress discoloration over time, particularly discoloration over time due to heat and / or light, in preparations containing diphenhydramine or a salt thereof and ascorbic acid or a salt thereof. Was not known to.
Further, the methods disclosed in Patent Documents 1 to 10 suppress discoloration due to one of light and heat, and no effective method for discoloration due to both light and heat has been known so far.
本発明は、ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する外用組成物における経時的な変色、特に熱及び／又は光による経時的な変色を抑制することを目的とする。 An object of the present invention is to suppress discoloration over time in an external composition containing diphenhydramine or a salt thereof and ascorbic acid or a salt thereof, particularly discoloration over time due to heat and / or light.
本発明者らは、上記課題を解決するために鋭意研究した結果、ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する外用組成物に、ムコ多糖類（好ましくは、ヘパリン類似物質、コンドロイチン硫酸又はその塩、ヒアルロン酸又はその塩、ヒアルロン酸誘導体又はその塩、及びデルマタン硫酸又はその塩；特に好ましくはヘパリン類似物質）を共存させることにより、当該外用組成物の経時的な変色を抑制し得ることを見出し、本発明を完成するに至った。 As a result of diligent research to solve the above problems, the inventors of the present invention have added mucopolysaccharides (preferably heparin-like substances, chondroitin sulfate or chondroitin sulfate) to an external composition containing diphenhydramine or a salt thereof and ascorbic acid or a salt thereof. The salt, hyaluronic acid or a salt thereof, a hyaluronic acid derivative or a salt thereof, and dermatan sulfate or a salt thereof; As a result, the present invention has been completed.
従って、本発明は以下を提供する。
〔１〕ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する外用組成物において、ムコ多糖類の１種又は２種以上を共存させる、ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する外用組成物の変色抑制方法。
〔２〕ムコ多糖類が、ヘパリン類似物質、コンドロイチン硫酸又はその塩、ヒアルロン酸又はその塩、ヒアルロン酸誘導体又はその塩、及びデルマタン硫酸又はその塩からなる群から選択される１種又は２種以上である、〔１〕に記載の方法。
〔３〕ムコ多糖類が、ヘパリン類似物質及びコンドロイチン硫酸又はその塩からなる群から選択される１種又は２種以上である、〔１〕に記載の方法。
〔４〕ジフェンヒドラミン又はその塩を含有する外用組成物が、乳化物である、〔１〕〜〔３〕のいずれかに記載の方法。
〔５〕アスコルビン酸又はその塩を含有する外用組成物が、液剤である、〔１〕〜〔３〕のいずれかに記載の方法。
〔６〕ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩１重量部に対して、ムコ多糖類の１種又は２種以上を０．００３〜１０重量部共存させる、〔１〕〜〔５〕のいずれかに記載の方法。
〔７〕変色が、熱及び／又は光によるものである、〔１〕〜〔６〕のいずれかに記載の方法。
Accordingly, the present invention provides the following.
[1] A composition for external use containing diphenhydramine or a salt thereof and ascorbic acid or a salt thereof in which one or more mucopolysaccharides coexist in a composition for external use containing diphenhydramine or a salt thereof and ascorbic acid or a salt thereof Method for suppressing discoloration of objects.
[2] One or more mucopolysaccharides selected from the group consisting of heparin analogs, chondroitin sulfate or salts thereof, hyaluronic acid or salts thereof, hyaluronic acid derivatives or salts thereof, and dermatan sulfate or salts thereof The method according to [1], wherein
[3] The method according to [1], wherein the mucopolysaccharide is one or more selected from the group consisting of a heparin-like substance and chondroitin sulfate or a salt thereof.
[4] The method according to any one of [1] to [3], wherein the external composition containing diphenhydramine or a salt thereof is an emulsion.
[5] The method according to any one of [1] to [3], wherein the external composition containing ascorbic acid or a salt thereof is a liquid agent.
[6] Any of [1] to [5], in which 0.003 to 10 parts by weight of one or more mucopolysaccharides coexist with 1 part by weight of diphenhydramine or a salt thereof and ascorbic acid or a salt thereof. The method of crab.
[7] The method according to any one of [1] to [6], wherein the color change is caused by heat and / or light.
〔８〕ムコ多糖類の１種又は２種以上を有効成分とする、ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する外用組成物の変色抑制剤。
〔９〕ムコ多糖類が、ヘパリン類似物質、コンドロイチン硫酸又はその塩、ヒアルロン酸又はその塩、ヒアルロン酸誘導体又はその塩、及びデルマタン硫酸又はその塩からなる群から選択される１種又は２種以上である、〔８〕に記載の変色抑制剤。
〔１０〕ムコ多糖類が、ヘパリン類似物質及びコンドロイチン硫酸又はその塩からなる群から選択される１種又は２種以上である、〔８〕に記載の変色抑制剤。
〔１１〕ジフェンヒドラミン又はその塩を含有する外用組成物が、乳化物である、〔８〕〜〔１０〕のいずれかに記載の変色抑制剤。
〔１２〕アスコルビン酸又はその塩を含有する外用組成物が、液剤である、〔８〕〜〔１０〕のいずれかに記載の変色抑制剤。
〔１３〕ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩１重量部に対して、ムコ多糖類の１種又は２種以上を０．００３〜１０重量部共存させる、〔８〕〜〔１２〕のいずれかに記載の変色抑制剤。
〔１４〕変色が、熱及び／又は光によるものである、〔８〕〜〔１３〕のいずれかに記載の変色抑制剤。
[8] A discoloration inhibitor for a composition for external use containing diphenhydramine or a salt thereof and ascorbic acid or a salt thereof containing one or more mucopolysaccharides as active ingredients.
[9] One or more mucopolysaccharides selected from the group consisting of heparin analogs, chondroitin sulfate or salts thereof, hyaluronic acid or salts thereof, hyaluronic acid derivatives or salts thereof, and dermatan sulfate or salts thereof The discoloration inhibitor according to [8].
[10] The discoloration inhibitor according to [8], wherein the mucopolysaccharide is one or more selected from the group consisting of a heparin-like substance and chondroitin sulfate or a salt thereof.
[11] The discoloration inhibitor according to any one of [8] to [10], wherein the external composition containing diphenhydramine or a salt thereof is an emulsion.
[12] The discoloration inhibitor according to any one of [8] to [10], wherein the external composition containing ascorbic acid or a salt thereof is a liquid agent.
[13] Any of [8] to [12], in which 0.003 to 10 parts by weight of one or more mucopolysaccharides coexist with 1 part by weight of diphenhydramine or a salt thereof and ascorbic acid or a salt thereof. The discoloration inhibitor according to crab.
[14] The discoloration inhibitor according to any one of [8] to [13], wherein the discoloration is caused by heat and / or light.
本発明の方法によれば、ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する外用組成物の経時的な変色、特に熱及び／又は光による経時的な変色を抑制することができる。 According to the method of the present invention, discoloration over time of an external composition containing diphenhydramine or a salt thereof and ascorbic acid or a salt thereof, in particular, discoloration over time due to heat and / or light can be suppressed.
以下、本発明を詳細に説明する。なお、本明細書中において使用される用語は、特に他に言及しない限り、当該分野で通常用いられる意味で用いられていることが理解されるべきである。 Hereinafter, the present invention will be described in detail. It should be understood that the terms used in the present specification are used in the meaning normally used in the art unless otherwise specified.
本発明の外用組成物に含有されるジフェンヒドラミンは公知の化合物であり、ジフェンヒドラミンの塩としては、薬学的に許容されるものであれば、特に制限されず使用できる。ジフェンヒドラミン又はその塩は水和物の形態であってもよい。
ジフェンヒドラミンの塩の具体例としては、有機酸塩（例えば、酢酸塩、トリフルオロ酢酸塩、酪酸塩、パルミチン酸塩、ステアリン酸塩等のモノカルボン酸塩；フマル酸塩、マレイン酸塩、コハク酸塩、マロン酸塩等の多価カルボン酸塩；乳酸塩、酒石酸塩、クエン酸塩等のオキシカルボン酸塩；ラウリル硫酸塩、メタンスルホン酸塩、トルエンスルホン酸塩等の有機スルホン酸塩；等）、無機酸塩（例えば、塩酸塩、硫酸塩、硝酸塩、臭化水素酸塩、リン酸塩等）、有機塩基との塩（例えば、メチルアミン、トリエチルアミン、トリエタノールアミン、モルホリン、ピペラジン、ピロリジン、トリピリジン、ピコリン等の有機アミンとの塩等）、金属との塩（例えば、ナトリウム、カリウム等のアルカリ金属；カルシウム、マグネシウム等のアルカリ土類金属；アルミニウム；等の金属との塩等）、アンモニウム塩等が挙げられる。
Diphenhydramine contained in the composition for external use of the present invention is a known compound, and any salt of diphenhydramine can be used without particular limitation as long as it is pharmaceutically acceptable. Diphenhydramine or a salt thereof may be in the form of a hydrate.
Specific examples of diphenhydramine salts include organic acid salts (for example, monocarboxylic acid salts such as acetate, trifluoroacetate, butyrate, palmitate, stearate; fumarate, maleate, succinic acid). Polyvalent carboxylates such as salts and malonates; oxycarboxylates such as lactate, tartrate and citrate; organic sulfonates such as lauryl sulfate, methanesulfonate and toluenesulfonate; etc. ), Inorganic acid salts (eg, hydrochloride, sulfate, nitrate, hydrobromide, phosphate, etc.), salts with organic bases (eg, methylamine, triethylamine, triethanolamine, morpholine, piperazine, pyrrolidine) , Salts with organic amines such as tripyridine and picoline), salts with metals (for example, alkali metals such as sodium and potassium; calcium and magnesium) Alkaline earth metal; aluminum; a salt with a metal such like), ammonium salts.
本発明の外用組成物に配合するジフェンヒドラミン又はその塩の配合量は、所望の薬理作用を奏し得る限り特に制限されないが、外用組成物全体に対して、通常は０．１重量％以上、好ましくは０．５重量％以上、さらに好ましくは１重量％以上であり、配合上限は、通常１０重量％以下、好ましくは５重量％以下、さらに好ましくは２重量％以下とするのがよい。 The amount of diphenhydramine or a salt thereof to be blended in the composition for external use of the present invention is not particularly limited as long as the desired pharmacological action can be exerted, but is usually 0.1% by weight or more, preferably It is 0.5% by weight or more, more preferably 1% by weight or more, and the upper limit of blending is usually 10% by weight or less, preferably 5% by weight or less, more preferably 2% by weight or less.
本発明の外用組成物に含有されるアスコルビン酸は公知の化合物であり、アスコルビン酸の塩としては、薬学的に許容されるものであれば、特に制限されず使用できる。アスコルビン酸又はその塩は水和物の形態であってもよい。
アスコルビン酸の塩の具体例としては、有機塩基との塩（例えば、トリメチルアミン塩、トリエチルアミン塩、モノエタノールアミン塩、トリエタノールアミン塩、ピリジン塩などの第３級アミンとの塩、アルギニンなどの塩基性アンモニウム塩など）、無機塩基との塩（例えば、アンモニウム塩、ナトリウム塩、カリウム塩などのアルカリ金属塩、カルシウム塩、マグネシウム塩などのアルカリ土類金属塩、アルミニウム塩など）などが挙げられ、特に好ましい塩は、ナトリウム塩、カリウム塩である。具体的には、アスコルビン酸ナトリウム、アスコルビン酸モノリン酸エステルナトリウム、アスコルビン酸ジリン酸エステルナトリウム、アスコルビン酸トリリン酸エステルナトリウム、アスコルビン酸−２−硫酸エステルナトリウム等が挙げられる。
Ascorbic acid contained in the composition for external use of the present invention is a known compound, and any salt of ascorbic acid can be used without particular limitation as long as it is pharmaceutically acceptable. Ascorbic acid or a salt thereof may be in the form of a hydrate.
Specific examples of salts of ascorbic acid include salts with organic bases (for example, salts with tertiary amines such as trimethylamine salt, triethylamine salt, monoethanolamine salt, triethanolamine salt, pyridine salt, bases such as arginine) Salts with inorganic bases (for example, alkali metal salts such as ammonium salt, sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, aluminum salt, etc.) Particularly preferred salts are sodium salt and potassium salt. Specific examples include sodium ascorbate, sodium ascorbate monophosphate, sodium ascorbate diphosphate, sodium ascorbate triphosphate, sodium ascorbate-2-sulfate.
本発明の外用組成物に含有されるアスコルビン酸又はその塩は医薬品、医薬部外品または化粧品分野において皮膚外用剤の成分として市販されているアスコルビン酸又はその塩を用いることができる。本発明で用いるアスコルビン酸又はその塩の配合量は、本発明の効果を奏し得る限り特に制限されないが、皮膚外用剤全体に対して、通常は０．１重量％以上、好ましくは０．５重量％以上、さらに好ましくは１重量％以上であり、配合上限は、通常３０重量％以下、好ましくは１０重量％以下、さらに好ましくは５重量％以下とするのがよい。 Ascorbic acid or a salt thereof contained in the composition for external use of the present invention can be ascorbic acid or a salt thereof commercially available as a component of a skin external preparation in the pharmaceutical, quasi-drug or cosmetic field. The amount of ascorbic acid or a salt thereof used in the present invention is not particularly limited as long as the effect of the present invention can be obtained, but is usually 0.1% by weight or more, preferably 0.5% by weight with respect to the whole external preparation for skin. %, More preferably 1% by weight or more, and the upper limit of blending is usually 30% by weight or less, preferably 10% by weight or less, more preferably 5% by weight or less.
ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する外用組成物は、経時的に変色、特に熱及び／又は光によって経時的に変色するが、本発明の変色抑制方法は、ムコ多糖類を有効成分とする点を特徴とする。 The composition for external use containing diphenhydramine or a salt thereof and ascorbic acid or a salt thereof discolors over time, particularly discoloration over time due to heat and / or light, but the discoloration suppressing method of the present invention is effective for mucopolysaccharides. It is characterized by its component.
ムコ多糖類は、皮膚の天然保湿因子として知られ、優れた保湿効果を有していることから、本発明の変色抑制方法の有効成分としてムコ多糖類を共存させることにより、本発明の外用組成物は優れた保湿効果を奏することも期待される。 Mucopolysaccharide is known as a natural moisturizing factor for skin, and has an excellent moisturizing effect. Therefore, by making mucopolysaccharide coexist as an active ingredient in the method for inhibiting discoloration of the present invention, the composition for external use of the present invention The product is also expected to have an excellent moisturizing effect.
ムコ多糖類は、その基本骨格にアミノ糖とウロン酸とを含有する多糖類であって、動物の組織から得られる。ムコ多糖類の具体例としては、ヘパリン類似物質、コンドロイチン硫酸、デルマタン硫酸、ヒアルロン酸、ヘパラン硫酸、ヘパリン、ケラタン硫酸Ｉ及びＩＩ等、及びこれらの誘導体、並びにこれらの塩が挙げられる。 Mucopolysaccharide is a polysaccharide containing amino sugar and uronic acid in its basic skeleton, and is obtained from animal tissues. Specific examples of the mucopolysaccharide include heparin-like substances, chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparan sulfate, heparin, keratan sulfate I and II, and derivatives thereof, and salts thereof.
ヘパリン類似物質、コンドロイチン硫酸、デルマタン硫酸、ヒアルロン酸、ヘパラン硫酸、ヘパリン、ケラタン硫酸Ｉ及びＩＩ等及びこれらの誘導体の塩としては、薬学的・生学的に許容される塩が好ましい。例えば、ナトリウム、カリウム等のアルカリ金属塩；
マグネシウム、カルシウム等のアルカリ土類金属塩；アンモニウム塩；モノエタノールアミン等のアルカノールアミン塩；等を挙げることができ、好ましくはナトリウム塩等のアルカリ金属塩である。
As salts of heparin-like substances, chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparan sulfate, heparin, keratan sulfate I and II, and derivatives thereof, pharmaceutically and biologically acceptable salts are preferable. For example, alkali metal salts such as sodium and potassium;
Examples include alkaline earth metal salts such as magnesium and calcium; ammonium salts; alkanolamine salts such as monoethanolamine; and preferably alkali metal salts such as sodium salts.
本発明に用いるムコ多糖類の由来は特に制限されず、医薬品、医薬部外品、又は化粧品の分野において通常用いられ得るものを特に限定されず用いることができる。
本発明において、ムコ多糖類は、１種単独で使用しても、また２種以上を任意に組み合わせて使用してもよい。また、ムコ多糖類は、市販品がある場合、市販品をそのまま使用してもよい。
The origin of the mucopolysaccharide used in the present invention is not particularly limited, and those that can be usually used in the field of pharmaceuticals, quasi drugs, or cosmetics can be used without particular limitation.
In the present invention, mucopolysaccharides may be used singly or in combination of two or more. Moreover, when there are commercially available mucopolysaccharides, the commercially available products may be used as they are.
本発明の組成物において、ムコ多糖類の平均分子量は特に制限されないが、通常は１０００〜４００万、好ましくは１０００〜１２０万であり、より好ましくは５０００〜１００万、特に好ましくは５０００〜４０万である。 In the composition of the present invention, the average molecular weight of the mucopolysaccharide is not particularly limited, but is usually 1,000 to 4,000,000, preferably 1,000 to 1,200,000, more preferably 5,000 to 1,000,000, particularly preferably 5,000 to 400,000. It is.
本発明に用いられるムコ多糖類としては、具体的には、ヘパリン類似物質；コンドロイチン硫酸、コンドロイチン硫酸ナトリウム等のコンドロイチン硫酸又はその塩；デルマタン硫酸、デルマタン硫酸ナトリウム等のデルマタン硫酸またはその塩；ヒアルロン酸、ヒアルロン酸ナトリウム、ヒアルロン酸カリウム、ヒアルロン酸マグネシウム、ヒアルロン酸カルシウム等のヒアルロン酸又はその塩；アセチルヒアルロン酸、アセチルヒアルロン酸ナトリウム、アセチルヒアルロン酸カリウム、アセチルヒアルロン酸マグネシウム、アセチルヒアルロン酸カルシウム等のヒアルロン酸誘導体又はその塩；ヘパラン硫酸；ヘパリン；ケラタン硫酸Ｉ及びＩＩ；等や、これらの混合物等が挙げられる。 Specific examples of mucopolysaccharides used in the present invention include heparin-like substances; chondroitin sulfate such as chondroitin sulfate and sodium chondroitin sulfate or salts thereof; dermatan sulfate such as dermatan sulfate and sodium dermatan sulfate; or salts thereof; hyaluronic acid Hyaluronic acid or its salts such as sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate, calcium hyaluronate; hyaluronic acid such as acetyl hyaluronic acid, sodium acetyl hyaluronate, potassium acetyl hyaluronate, magnesium acetyl hyaluronate, calcium acetyl hyaluronate Examples include acid derivatives or salts thereof; heparan sulfate; heparin; keratan sulfate I and II; and mixtures thereof.
本発明に用いられるムコ多糖類としては、本発明の効果の発揮の観点から、好ましくはヘパリン類似物質；コンドロイチン硫酸、コンドロイチン硫酸ナトリウム等のコンドロイチン硫酸又はその塩；ヒアルロン酸、ヒアルロン酸ナトリウム等のヒアルロン酸又はその塩；アセチルヒアルロン酸、アセチルヒアルロン酸ナトリウム等のヒアルロン酸誘導体又はその塩；デルマタン硫酸、デルマタン硫酸ナトリウム等のデルマタン硫酸またはその塩；等が、より好ましくはヘパリン類似物質や、コンドロイチン硫酸、コンドロイチン硫酸ナトリウム等のコンドロイチン硫酸又はその塩等が、特に好ましくはヘパリン類似物質が挙げられる。 The mucopolysaccharide used in the present invention is preferably a heparin-like substance; chondroitin sulfate such as chondroitin sulfate or sodium chondroitin sulfate or a salt thereof; hyaluronic acid such as hyaluronic acid or sodium hyaluronate from the viewpoint of exerting the effects of the present invention. An acid or a salt thereof; a hyaluronic acid derivative such as acetyl hyaluronic acid or sodium acetyl hyaluronic acid or a salt thereof; a dermatan sulfate such as dermatan sulfate or sodium dermatan sulfate or a salt thereof; and more preferably heparin-like substances, chondroitin sulfate A chondroitin sulfate such as sodium chondroitin sulfate or a salt thereof is particularly preferably a heparin-like substance.
ここで、ヘパリン類似物質とは、コンドロイチン多硫酸等の多硫酸化ムコ多糖の総称を意味し、ムコ多糖を構成する単糖１分子当たり平均０．５〜５分子、好ましくは平均０．６〜３分子の硫酸基を有するのが好ましい。より具体的には、ヘパリン類似物質は、ヘパリン、コンドロイチンポリ硫酸と呼ばれるコンドロイチン硫酸Ｄやコンドロイチン硫酸Ｅ等を含有する。
ヘパリン類似物質は、ムコ多糖を硫酸化することにより得ることもできるし、ウシ、ブタ等の動物の気管支を含む内臓より水性担体を用いて抽出・精製したり、その後必要に応じて硫酸化することによっても得ることもできる。このようなヘパリン類似物質は、医薬化粧品原料として開発されているため、このような市販品を利用することもできる。
本発明の外用組成物において、ヘパリン類似物質としては、日本薬局方外医薬品規格に収戴されているものが好適に使用される。
Here, the heparin-like substance means a generic name of polysulfated mucopolysaccharides such as chondroitin polysulfate, and an average of 0.5 to 5 molecules, preferably an average of 0.6 to 1 molecule per monosaccharide constituting the mucopolysaccharide. It preferably has three molecules of sulfate groups. More specifically, the heparin-like substance contains heparin, chondroitin sulfate D or chondroitin sulfate E called chondroitin polysulfate.
Heparin-like substances can be obtained by sulfating mucopolysaccharides, or extracted and purified from internal organs including bronchi of animals such as cattle and pigs using an aqueous carrier, and then sulfated as necessary. Can also be obtained. Since such a heparin-like substance has been developed as a raw material for pharmaceutical cosmetics, such a commercial product can be used.
In the composition for external use of the present invention, as the heparin-like substance, those that are included in the Japanese Pharmacopoeia pharmaceutical standards are preferably used.
本発明の外用組成物に配合するムコ多糖類の配合量は、本願効果を奏し得る限り特に制限されないが、外用組成物全体に対して、通常は０．００５重量％以上、好ましくは０．０１重量％以上、さらに好ましくは０．０５重量％以上、特に好ましくは０．１重量％以上であり、配合上限は、通常１０重量％以下、好ましくは５重量％以下、さらに好ましくは１重量％以下、特に好ましくは０．５重量％以下とするのがよい。 The amount of mucopolysaccharide blended in the composition for external use of the present invention is not particularly limited as long as the effect of the present invention can be obtained, but is usually 0.005% by weight or more, preferably 0.01% with respect to the entire composition for external use. % By weight or more, more preferably 0.05% by weight or more, particularly preferably 0.1% by weight or more, and the upper limit of blending is usually 10% by weight or less, preferably 5% by weight or less, more preferably 1% by weight or less. Particularly preferably, the content is 0.5% by weight or less.
本発明の外用組成物におけるジフェンヒドラミン又はその塩とムコ多糖類との重量比は、本願効果を奏し得る限り特に制限されないが、ジフェンヒドラミン又はその塩１重量部に対して、ムコ多糖類が通常は０．００５〜１０重量部、好ましくは０．０１〜５重量部、さらに好ましくは０．０５〜２重量部、特に好ましくは０．１〜１重量部の範囲内とするのがよい。 The weight ratio of diphenhydramine or a salt thereof and mucopolysaccharide in the composition for external use of the present invention is not particularly limited as long as the effect of the present invention can be achieved, but the mucopolysaccharide is usually 0 with respect to 1 part by weight of diphenhydramine or a salt thereof. 0.005 to 10 parts by weight, preferably 0.01 to 5 parts by weight, more preferably 0.05 to 2 parts by weight, and particularly preferably 0.1 to 1 part by weight.
本発明の外用組成物におけるアスコルビン酸又はその塩とムコ多糖類との重量比は、本願効果を奏し得る限り特に制限されないが、アスコルビン酸又はその塩１重量部に対して、ムコ多糖類が通常は０．００３〜１０重量部、好ましくは０．００５〜１重量部、さらに好ましくは０．０１〜０．３重量部の範囲内とするのがよい。 The weight ratio of ascorbic acid or a salt thereof to mucopolysaccharide in the composition for external use of the present invention is not particularly limited as long as the effect of the present invention can be achieved, but mucopolysaccharide is usually used with respect to 1 part by weight of ascorbic acid or a salt thereof. Is 0.003 to 10 parts by weight, preferably 0.005 to 1 part by weight, more preferably 0.01 to 0.3 part by weight.
本発明の外用組成物は、その用途に応じて、種々の形態に調製することができ、例えば、クリーム、乳液、ゲル乳液、ローション、美容液、化粧水、軟膏剤、固形剤等の形態が挙げられる。なかでも、広範囲に塗布しやすいことから、本発明の実施形態としてはクリーム、乳液、ゲル乳液等の乳化物、ローション、美容液、化粧水等の液剤が好ましい。 The composition for external use of the present invention can be prepared in various forms according to its use. For example, the form of cream, emulsion, gel emulsion, lotion, cosmetic liquid, lotion, ointment, solid preparation, etc. Can be mentioned. Especially, since it is easy to apply | coat in a wide range, as an embodiment of this invention, emulsions, such as cream, a milky lotion, a gel milky lotion, and liquid agents, such as lotion, a cosmetic liquid, and a lotion, are preferable.
本発明の外用組成物には、保存安定性や粘度等の品質を損なわず、また本発明の効果を損なわない量的及び質的範囲内で、必要に応じて医薬品、医薬部外品または化粧品分野において一般的に用いられる各種の成分、例えば水、油性成分（例えば、炭化水素、植物油、エステル油、高級アルコール、シリコーン油、脂肪酸等）、多価アルコール、増粘剤、低級アルコール、界面活性剤、保存剤、ｐＨ調整剤、安定化剤、刺激軽減剤、防腐剤、着色剤、分散剤、香料等を配合することができる。なお、これらの成分は１種単独で、または２種以上を任意に組み合わせて配合することができる。またこれらの成分の配合量は、本発明の効果を奏すれば特に制限されないが、望ましくは薬学上許容される上限配合量を限度に適宜選択される。 The composition for external use of the present invention includes a pharmaceutical, a quasi-drug, or a cosmetic as needed within a quantitative and qualitative range that does not impair the quality such as storage stability and viscosity and does not impair the effects of the present invention. Various components commonly used in the field, such as water, oily components (eg, hydrocarbons, vegetable oils, ester oils, higher alcohols, silicone oils, fatty acids, etc.), polyhydric alcohols, thickeners, lower alcohols, surface activity Agents, preservatives, pH adjusters, stabilizers, irritation reducers, preservatives, colorants, dispersants, fragrances and the like can be blended. In addition, these components can be mix | blended individually by 1 type or in combination of 2 or more types arbitrarily. Moreover, the compounding amounts of these components are not particularly limited as long as the effects of the present invention are achieved, but are desirably selected as appropriate with the upper limit compounding amount acceptable for pharmacology.
本発明の外用組成物には、該組成物に所望の効果を持たせるため、さらに有効成分を配合することができる。本発明において有効成分とは、薬理活性成分や生理活性成分等の皮膚に対して有用な効果を有する成分で、特に制限されないが、例えば、非ステロイド性抗炎症剤、ビタミン類、美白剤、抗シワ剤、消炎鎮痛剤、抗真菌剤、ステロイド剤、育毛剤、痩身剤、局所麻酔剤、鎮痒剤、抗菌剤、抗ウイルス剤、角質軟化剤、保湿剤、収斂剤、抗酸化剤、発毛抑制剤、紫外線吸収剤、紫外線散乱剤等が挙げられる。これらの成分は１種単独でまたは２種以上を組み合わせて用いることができる。またこれらの成分の配合量は、本発明の効果を奏すれば特に制限されないが、望ましくは薬学上許容される上限配合量を限度に適宜選択される。 In the composition for external use of the present invention, an active ingredient can be further blended in order to give the composition a desired effect. In the present invention, the active ingredient is a component having a useful effect on the skin, such as a pharmacologically active ingredient and a physiologically active ingredient, and is not particularly limited. For example, non-steroidal anti-inflammatory agents, vitamins, whitening agents, Wrinkles, anti-inflammatory analgesics, antifungals, steroids, hair restorers, slimming agents, local anesthetics, antipruritics, antibacterial agents, antiviral agents, keratin softeners, moisturizers, astringents, antioxidants, hair growth Examples thereof include an inhibitor, an ultraviolet absorber, and an ultraviolet scattering agent. These components can be used individually by 1 type or in combination of 2 or more types. Further, the blending amounts of these components are not particularly limited as long as the effects of the present invention are achieved, but are desirably selected as appropriate with the upper limit blending amount acceptable for pharmacology.
本発明の外用組成物は、通常、容器に充填されて使用される。このような容器としては、使用目的・用途に応じ、適宜選択した形状、材質の容器に収容し、使用することができ、当該技術分野において通常使用されるものであれば、特に制限されず使用できる。
容器（本体、キャップ、吐出部材、中栓、シール部材等）の材質としては、最内層が外用組成物の保存安定性等や、容器の耐薬品性、強度、柔軟性、耐候性等を考慮して適宜選択すればよく、例えば、ポリエチレン、ポリプロピレン、ポリエチレンテレフタレート、ポリスチレン、アルミ、ポリ塩化ビニル、ＡＢＳ樹脂、エチレン−ビニルアルコール樹脂、アクリロニトリル・スチレン樹脂、エポキシ樹脂、ポリアミド・イミド樹脂及びガラス等が挙げられる。好ましくは、容器材質として最内層がポリエチレン、ポリプロピレン、ポリエチレンテレフタレート、アルミ、エポキシ樹脂、ポリアミド・イミド樹脂及びガラスの容器が挙げられる。また、これらの容器樹脂を使用した積層体を用いてもよい。
The composition for external use of the present invention is usually used by being filled in a container. As such a container, it can be accommodated and used in a container of a shape and material appropriately selected according to the purpose of use and use, and is not particularly limited as long as it is normally used in the technical field. it can.
As the material of the container (main body, cap, discharge member, inner stopper, seal member, etc.), the innermost layer takes into consideration the storage stability of the composition for external use and the chemical resistance, strength, flexibility, weather resistance, etc. of the container For example, polyethylene, polypropylene, polyethylene terephthalate, polystyrene, aluminum, polyvinyl chloride, ABS resin, ethylene-vinyl alcohol resin, acrylonitrile / styrene resin, epoxy resin, polyamide / imide resin, glass, etc. Can be mentioned. Preferably, the container material includes a container whose innermost layer is polyethylene, polypropylene, polyethylene terephthalate, aluminum, epoxy resin, polyamide-imide resin, and glass. Moreover, you may use the laminated body using these container resins.
本発明の外用組成物は、様々な症状や疾患の治療、予防又は改善用の組成物として用いることができる。本発明の外用組成物の外皮への適用量や用法は特に制限されず、該組成物は通常、一日数回、適量を皮膚等の外皮に塗布する等して用いることができる。 The composition for external use of the present invention can be used as a composition for treating, preventing or ameliorating various symptoms and diseases. The application amount and usage of the external composition of the present invention to the outer skin are not particularly limited, and the composition can be used usually by applying an appropriate amount to the outer skin such as skin several times a day.
本発明の外用組成物は、ジフェンヒドラミン又はその塩及びムコ多糖類が、治療、予防又は改善効果を奏する症状や疾患に対して用いるのが特に好ましい。このような症状、疾患としては、例えば、痒み症状；皮膚の乾燥に起因する症状；痒み症状や皮膚の乾燥に起因する症状を示す疾患；等が挙げられる。
皮膚の乾燥に起因する症状の具体例としては、皮膚表面の落屑、粉ふき、けばだち、かさつき、ひび、あかぎれ、ひじ・ひざ・かかと・くるぶし等の角化、顔の小じわ、皮膚柔軟性の低下、手指のあれ、痒み、乾燥肌（ドライスキン）、敏感肌、皮膚のかぶれ、紅斑、アトピー肌、肌荒れ等がある。
痒み症状や皮膚の乾燥に起因する症状を示す疾患の具体例としては、乾皮症、老人性乾皮症、小児乾燥性皮膚、尋常性鱗癬（鮫肌）、アトピー性皮膚炎、アレルギー性皮膚炎、皮脂減少性湿疹、敏感肌、季節性乾皮症、水性掻痒症、主婦湿疹、皮膚炎、かぶれ、じんましん、虫さされ、湿疹、ただれ、あせも、しもやけ等が挙げられる。
本発明の外用組成物は、痒みを伴う、皮膚の乾燥に起因する症状を示す疾患（例えば、乾皮症、老人性乾皮症、小児乾燥性皮膚等）に対して、特に有効である。
The external composition of the present invention is particularly preferably used for symptoms and diseases in which diphenhydramine or a salt thereof and a mucopolysaccharide exhibit a therapeutic, preventive or improving effect. Examples of such symptoms and diseases include itch symptoms; symptoms caused by dry skin; diseases showing itch symptoms and symptoms caused by dry skin; and the like.
Specific examples of symptoms caused by dry skin include desquamation on the skin surface, dusting, bristle, roughness, cracks, scratches, keratinization of elbows, knees, heels and ankles, facial fine lines, skin There are a decrease in flexibility, finger tingling, itching, dry skin, sensitive skin, skin irritation, erythema, atopic skin, rough skin, and the like.
Specific examples of itching and illness caused by dry skin include xeroderma, senile xeroderma, pediatric dry skin, acne vulgaris (skin skin), atopic dermatitis, allergic skin Inflammation, sebum-reducing eczema, sensitive skin, seasonal psoriasis, aqueous pruritus, housewife eczema, dermatitis, rash, hives, insect bites, eczema, soreness, dry skin, moistness and the like.
The composition for external use of the present invention is particularly effective for diseases (for example, xeroderma, senile xerosis, pediatric dry skin, etc.) that are accompanied by itching and exhibit symptoms caused by dry skin.
本発明の外用組成物は、アスコルビン酸又はその塩及びムコ多糖類が、治療、予防又は改善効果を奏する症状や疾患に対して用いるのが特に好ましい。このような症状、疾患としては、例えば炎症症状；皮膚の炎症に起因する症状；肌あれ症状や皮膚の炎症に起因する症状を示す疾患；にきび等が挙げられる。皮膚の炎症に起因する症状の具体例としては、ひび、あかぎれ、手指のあれ、痒み、乾燥肌（ドライスキン）、敏感肌、皮膚のかぶれ、紅斑、アトピー肌、肌荒れ、日焼けによるしみ、そばかす等がある。
本発明の外用組成物は、皮膚の炎症に起因する症状を示す疾患（例えば、にきび、日焼けによるしみ、そばかす）に対して、特に有効である。
The external composition of the present invention is particularly preferably used for symptoms and diseases in which ascorbic acid or a salt thereof and mucopolysaccharide exhibit therapeutic, preventive or ameliorating effects. Examples of such symptoms and diseases include inflammatory symptoms; symptoms caused by skin inflammation; diseases showing skin roughness and symptoms caused by skin inflammation; acne and the like. Specific examples of symptoms caused by skin irritation include cracks, redness, finger tingling, itching, dry skin, sensitive skin, skin irritation, erythema, atopic skin, rough skin, sunburn spots, freckles, etc. There is.
The composition for external use of the present invention is particularly effective for diseases (for example, acne, sunburn spots, freckles) that show symptoms caused by skin inflammation.
以下に、実施例に基づいて本発明を詳細に説明するが、本発明はこれらの実施例によって限定されるものではない。なお、下記の各実施例において％とは特に言及しない限り、質量（Ｗ／Ｗ）％を意味するものとする。 EXAMPLES The present invention will be described in detail below based on examples, but the present invention is not limited to these examples. In the following examples,% means mass (W / W)% unless otherwise specified.
試験例１ ジフェンヒドラミン含有クリームの熱安定性及び光安定性試験
油相（パルミチン酸イソプロピル、流動パラフィン、セトマクロゴール、モノステアリン酸グリセリン、セタノール、白色ワセリンを混合溶解したもの）にジフェンヒドラミンを加え、７０℃まで加熱した。同様に水相（精製水、濃グリセリン、パラオキシ安息香酸メチル、カルボキシビニルポリマー、エデト酸ナトリウムを混合攪拌したもの）にヘパリン類似物質を加え、７０℃に加熱した。２相（油相、水相）を高温で攪拌・乳化し、室温まで冷却して、表１に示す組成の実施例１のクリームを得た。
比較例１のクリームは、ヘパリン類似物質を加えない以外は実施例１のクリームと同様にして、製造した。
Test Example 1 Heat stability and light stability of diphenhydramine-containing cream Diphenhydramine was added to an oil phase (mixed and dissolved in isopropyl palmitate, liquid paraffin, cetomacrogol, glyceryl monostearate, cetanol and white petrolatum), 70 Heated to ° C. Similarly, a heparin-like substance was added to an aqueous phase (purified water, concentrated glycerin, methyl paraoxybenzoate, carboxyvinyl polymer, sodium edetate) and heated to 70 ° C. Two phases (an oil phase and an aqueous phase) were stirred and emulsified at a high temperature and cooled to room temperature to obtain a cream of Example 1 having the composition shown in Table 1.
The cream of Comparative Example 1 was produced in the same manner as the cream of Example 1 except that no heparin-like substance was added.
熱安定性試験
５０ｍｌの透明なねじ口ビンに、実施例１及び比較例１の外用組成物をそれぞれ約４０ｇ入れ、６０℃にて３日間保存し、目視にて色の変化を観察した。結果を表１に示す。
光安定性試験
５０ｍｌの透明なねじ口ビンに、実施例１及び比較例１の組成物をそれぞれ約４０ｇ入れ、２０〜２５℃にて光照射を行い（総照度１２０万ｌｕｘ・ｈｒ）、目視にて色の変化を観察した。結果を表１に示す。
Thermal Stability Test About 40 g of the composition for external use of Example 1 and Comparative Example 1 was put in a 50 ml transparent screw mouth bottle, respectively, stored at 60 ° C. for 3 days, and the color change was observed visually. The results are shown in Table 1.
Light stability test About 40 g of the composition of Example 1 and Comparative Example 1 were placed in a 50 ml transparent screw mouth bottle, respectively, and irradiated with light at 20 to 25 ° C. (total illuminance of 1.2 million lux · hr). The change in color was observed. The results are shown in Table 1.
表１に示した通り、熱及び光安定性試験のいずれにおいても、ヘパリン類似物質を含有する実施例１は、ヘパリン類似物質を含有しない比較例１と比較して、外用組成物の経時的な変色が抑制されていることが認められた。 As shown in Table 1, in both heat and light stability tests, Example 1 containing a heparin-like substance was more time-dependent than that of Comparative Example 1 containing no heparin-like substance. It was observed that discoloration was suppressed.
試験例２ ジフェンヒドラミン含有乳液の熱安定性及び光安定性試験
油相（パルミチン酸イソプロピル、フィトステロール、ポリオキシエチレン硬化ヒマシ油、白色ワセリンを混合溶解したもの）にジフェンヒドラミンを加え、７０℃まで加熱した。同様に水相（精製水、濃グリセリン、パラオキシ安息香酸メチル、クエン酸ナトリウム、クエン酸を混合溶解したもの）にヘパリン類似物質を加え、７０℃に加熱した。２相（油相、水相）を高温で攪拌・乳化し、キサンタンガムを加え攪拌し、室温まで冷却して、表２に示す組成の実施例２の乳液を得た。
比較例２の乳液は、ヘパリン類似物質を加えない以外は実施例２の乳液と同様にして、製造した。
Test Example 2 Diphenhydramine was added to a heat stability and photostability test oil phase of diphenhydramine-containing emulsion (isopropyl palmitate, phytosterol, polyoxyethylene hydrogenated castor oil, white petrolatum mixed and dissolved), and heated to 70 ° C. Similarly, a heparin-like substance was added to an aqueous phase (purified water, concentrated glycerin, methyl parahydroxybenzoate, sodium citrate, and citric acid) and heated to 70 ° C. Two phases (oil phase, aqueous phase) were stirred and emulsified at high temperature, xanthan gum was added and stirred, and cooled to room temperature to obtain an emulsion of Example 2 having the composition shown in Table 2.
The emulsion of Comparative Example 2 was produced in the same manner as the emulsion of Example 2 except that no heparin-like substance was added.
熱安定性試験
５０ｍｌの透明なねじ口ビンに、実施例１及び比較例１の外用組成物をそれぞれ約４０ｇ入れ、６０℃にて１日間保存し、目視にて色の変化を観察した。結果を表２に示す。
Thermal Stability Test About 40 g of the composition for external use of Example 1 and Comparative Example 1 was put in a 50 ml transparent screw mouth bottle, respectively, stored at 60 ° C. for 1 day, and the color change was observed visually. The results are shown in Table 2.
表２に示した通り、熱安定性試験において、ヘパリン類似物質を含有する実施例２は、
ヘパリン類似物質を含有しない比較例２と比較して、外用組成物の経時的な変色が抑制されていることが認められた。なお、熱安定性と同様に、試験例２の外用組成物の光安定性についても試験例1と同様の傾向が認められる。
As shown in Table 2, in the thermal stability test, Example 2 containing a heparin analog was
It was confirmed that discoloration over time of the composition for external use was suppressed as compared with Comparative Example 2 containing no heparin-like substance. In addition, the tendency similar to Test Example 1 is recognized also about the light stability of the composition for external use of Test Example 2 similarly to thermal stability.
試験例３ アスコルビン酸含有ローション剤（美容液）の熱安定性及び光安定性試験
精製水、濃グリセリン、１．３−ブチレングリコール、プロピレングリコール、パラオキシ安息香酸メチル、エデト酸ナトリウム、アスコルビン酸、ヘパリン類似物質を４０℃で混合溶解し、室温まで冷却して、表１に示す組成の実施例３のローション剤（美容液）を得た。
比較例３のローション剤（美容液）は、ヘパリン類似物質を加えない以外は実施例３のローション剤（美容液）と同様にして、製造した。
Test Example 3 Thermal Stability and Light Stability Test of Ascorbic Acid-Containing Lotion (Cosmetic Liquid) Purified water, concentrated glycerin, 1.3-butylene glycol, propylene glycol, methyl paraoxybenzoate, sodium edetate, ascorbic acid, heparin The similar substances were mixed and dissolved at 40 ° C. and cooled to room temperature to obtain the lotion preparation (beauty liquid) of Example 3 having the composition shown in Table 1.
The lotion preparation (beauty liquid) of Comparative Example 3 was produced in the same manner as the lotion preparation (beauty liquid) of Example 3 except that no heparin-like substance was added.
熱安定性試験
５０ｍｌの透明なねじ口ビンに、実施例３及び比較例３の外用組成物をそれぞれ約４０ｇ入れ、６０℃にて３日間保存し、目視にて色の変化を観察した。結果を表３に示す。
光安定性試験
５０ｍｌの透明なねじ口ビンに、実施例１及び比較例１の組成物をそれぞれ約４０ｇ入れ、２０〜２５℃にて光照射を行い（総照度１２０万ｌｕｘ・ｈｒ）、目視にて色の変化を観察した。結果を表３に示す。
Thermal Stability Test About 40 g of the composition for external use of Example 3 and Comparative Example 3 was put in a 50 ml transparent screw mouth bottle, respectively, stored at 60 ° C. for 3 days, and the color change was observed visually. The results are shown in Table 3.
Light stability test About 40 g of the composition of Example 1 and Comparative Example 1 were placed in a 50 ml transparent screw mouth bottle, respectively, and irradiated with light at 20 to 25 ° C. (total illuminance of 1.2 million lux · hr). The change in color was observed. The results are shown in Table 3.
表３に示した通り、熱及び光安定性試験のいずれにおいても、ヘパリン類似物質を含有する実施例３は、ヘパリン類似物質を含有しない比較例３と比較して、外用組成物の経時的な変色が抑制されていることが認められた。 As shown in Table 3, in both the heat and light stability tests, Example 3 containing a heparin-like substance was more time-dependent than that of Comparative Example 3 containing no heparin-like substance. It was observed that discoloration was suppressed.
以下に製剤実施例を挙げるが、本発明はこれらの実施例に限られるものではない。製剤実施例を収容する容器素材としては、最内層が、ポリエチレン、ポリプロピレン、ポリエチレンテレフタレート、アルミ、エポキシ樹脂、ポリアミド・イミド樹脂及びガラスの容器を用いることができる。なお、各配合成分の単位は重量（Ｗ／Ｗ）％を意味するものとする。 Formulation examples are given below, but the present invention is not limited to these examples. As the container material that accommodates the formulation examples, a container whose innermost layer is polyethylene, polypropylene, polyethylene terephthalate, aluminum, epoxy resin, polyamide / imide resin, and glass can be used. In addition, the unit of each compounding component shall mean weight (W / W)%.
Claims (8)
A discoloration inhibitor for a composition for external use containing diphenhydramine or a salt thereof and ascorbic acid or a salt thereof containing one or more mucopolysaccharides as active ingredients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010003318A JP5951173B2 (en) | 2009-01-09 | 2010-01-08 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009003549 | 2009-01-09 | ||
| JP2009003549 | 2009-01-09 | ||
| JP2010003318A JP5951173B2 (en) | 2009-01-09 | 2010-01-08 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015075704A Division JP2015120766A (en) | 2009-01-09 | 2015-04-02 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010180206A true JP2010180206A (en) | 2010-08-19 |
| JP2010180206A5 JP2010180206A5 (en) | 2013-02-28 |
| JP5951173B2 JP5951173B2 (en) | 2016-07-13 |
Family
ID=42762018
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010003318A Active JP5951173B2 (en) | 2009-01-09 | 2010-01-08 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2015075704A Pending JP2015120766A (en) | 2009-01-09 | 2015-04-02 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2016130714A Active JP6152202B2 (en) | 2009-01-09 | 2016-06-30 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2017104388A Pending JP2017141304A (en) | 2009-01-09 | 2017-05-26 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2018138913A Withdrawn JP2018162322A (en) | 2009-01-09 | 2018-07-24 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2020085557A Active JP7096285B2 (en) | 2009-01-09 | 2020-05-14 | A method for suppressing discoloration of an external composition containing diphenhydramine or a salt thereof and ascorbic acid or a salt thereof. |
| JP2021186727A Active JP7320581B2 (en) | 2009-01-09 | 2021-11-17 | Method for suppressing discoloration of topical composition containing diphenhydramine or its salt and ascorbic acid or its salt |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015075704A Pending JP2015120766A (en) | 2009-01-09 | 2015-04-02 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2016130714A Active JP6152202B2 (en) | 2009-01-09 | 2016-06-30 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2017104388A Pending JP2017141304A (en) | 2009-01-09 | 2017-05-26 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2018138913A Withdrawn JP2018162322A (en) | 2009-01-09 | 2018-07-24 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2020085557A Active JP7096285B2 (en) | 2009-01-09 | 2020-05-14 | A method for suppressing discoloration of an external composition containing diphenhydramine or a salt thereof and ascorbic acid or a salt thereof. |
| JP2021186727A Active JP7320581B2 (en) | 2009-01-09 | 2021-11-17 | Method for suppressing discoloration of topical composition containing diphenhydramine or its salt and ascorbic acid or its salt |
Country Status (1)
| Country | Link |
|---|---|
| JP (7) | JP5951173B2 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015199709A (en) * | 2014-03-31 | 2015-11-12 | 小林製薬株式会社 | External composition for skin |
| JP2017057145A (en) * | 2015-09-14 | 2017-03-23 | 小林製薬株式会社 | External composition |
| JP2018203673A (en) * | 2017-06-06 | 2018-12-27 | 小林製薬株式会社 | Sebum secretion promoter |
| WO2019131892A1 (en) * | 2017-12-27 | 2019-07-04 | ロート製薬株式会社 | External composition containing ascorbic acid and/or salt thereof |
| WO2020004194A1 (en) * | 2018-06-28 | 2020-01-02 | 小林製薬株式会社 | External-use composition |
| WO2020067132A1 (en) * | 2018-09-25 | 2020-04-02 | ロート製薬株式会社 | Topical composition containing ascorbic acid and/or salt thereof |
| JP2022183993A (en) * | 2021-05-31 | 2022-12-13 | ホーユー株式会社 | Composition for improving or repairing skin barrier function |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7313111B2 (en) * | 2017-06-06 | 2023-07-24 | 小林製薬株式会社 | Sebum secretion stimulator and composition for external use |
| JP2018203672A (en) * | 2017-06-06 | 2018-12-27 | 小林製薬株式会社 | Sebum secretion promoter |
| JP7153429B2 (en) * | 2017-06-22 | 2022-10-14 | 小林製薬株式会社 | Active oxygen scavenging agent |
| JP7464243B2 (en) * | 2019-09-17 | 2024-04-09 | ジャパンメディック株式会社 | Treatment for dry, itchy skin |
| JP2022094515A (en) * | 2020-12-15 | 2022-06-27 | 小林製薬株式会社 | Topical composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61233622A (en) * | 1985-04-09 | 1986-10-17 | Riken Vitamin Co Ltd | Eye lotion composition |
| JP2000229884A (en) * | 1999-02-04 | 2000-08-22 | Lion Corp | Skin lotion |
| JP2006151828A (en) * | 2004-11-25 | 2006-06-15 | Zeria Pharmaceut Co Ltd | Ophthalmological composition |
| JP2008081505A (en) * | 2007-11-02 | 2008-04-10 | Rohto Pharmaceut Co Ltd | External preparation for skin |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56138112A (en) * | 1980-03-31 | 1981-10-28 | Teijin Ltd | Suppository containing ascorbic acid or sodium ascorbate |
| JPH0952848A (en) * | 1995-08-07 | 1997-02-25 | Pola Chem Ind Inc | Skin preparation for external use |
| JP3687277B2 (en) * | 1997-06-10 | 2005-08-24 | サンスター株式会社 | Whitening cosmetics |
| JP3262091B2 (en) * | 1998-12-25 | 2002-03-04 | ライオン株式会社 | Eyewash composition, method for eliminating stickiness of eyewash composition, and eyewash set |
| JP2001106621A (en) * | 1999-10-07 | 2001-04-17 | Lion Corp | Skin preparation for external use |
| JP2001158730A (en) * | 1999-12-03 | 2001-06-12 | Pola Chem Ind Inc | Cosmetic for improving dark skin color |
| JP4290841B2 (en) * | 2000-01-24 | 2009-07-08 | ポーラ化成工業株式会社 | Melanocyte dendrite elongation inhibitor and cosmetics containing the same |
| JP4247597B2 (en) * | 2002-08-29 | 2009-04-02 | ライオン株式会社 | Topical preparation |
| JP2004065949A (en) * | 2002-06-13 | 2004-03-04 | Lion Corp | Exothermic particles, exothermic compound and exothermic sheet using this compound |
| JP2004131383A (en) * | 2002-06-25 | 2004-04-30 | Lion Corp | Sheetlike pack |
| US20070129430A1 (en) * | 2003-10-07 | 2007-06-07 | Satomi Miyata | Agent for enhancing the production of collagen, their preparation and use |
| JP4789464B2 (en) * | 2004-01-13 | 2011-10-12 | ロート製薬株式会社 | Topical skin preparation |
| JP2006143605A (en) * | 2004-11-16 | 2006-06-08 | Miyao Shunsuke | Method for producing percutaneously administrative agent and orally administrative agent each promoting fibroblast proliferation |
| US20070134173A1 (en) * | 2005-12-09 | 2007-06-14 | The Procter & Gamble Company | Personal care compositions |
| JP5113371B2 (en) * | 2006-11-22 | 2013-01-09 | 日本精化株式会社 | Hydrolyzate of water-soluble polysaccharide derived from white jellyfish, antioxidant containing the same, cosmetic or skin external preparation, food |
| JP2010013378A (en) * | 2008-07-02 | 2010-01-21 | Mandom Corp | External preparation composition for skin |
-
2010
- 2010-01-08 JP JP2010003318A patent/JP5951173B2/en active Active
-
2015
- 2015-04-02 JP JP2015075704A patent/JP2015120766A/en active Pending
-
2016
- 2016-06-30 JP JP2016130714A patent/JP6152202B2/en active Active
-
2017
- 2017-05-26 JP JP2017104388A patent/JP2017141304A/en active Pending
-
2018
- 2018-07-24 JP JP2018138913A patent/JP2018162322A/en not_active Withdrawn
-
2020
- 2020-05-14 JP JP2020085557A patent/JP7096285B2/en active Active
-
2021
- 2021-11-17 JP JP2021186727A patent/JP7320581B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61233622A (en) * | 1985-04-09 | 1986-10-17 | Riken Vitamin Co Ltd | Eye lotion composition |
| JP2000229884A (en) * | 1999-02-04 | 2000-08-22 | Lion Corp | Skin lotion |
| JP2006151828A (en) * | 2004-11-25 | 2006-06-15 | Zeria Pharmaceut Co Ltd | Ophthalmological composition |
| JP2008081505A (en) * | 2007-11-02 | 2008-04-10 | Rohto Pharmaceut Co Ltd | External preparation for skin |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015199709A (en) * | 2014-03-31 | 2015-11-12 | 小林製薬株式会社 | External composition for skin |
| JP2017057145A (en) * | 2015-09-14 | 2017-03-23 | 小林製薬株式会社 | External composition |
| JP2018203673A (en) * | 2017-06-06 | 2018-12-27 | 小林製薬株式会社 | Sebum secretion promoter |
| WO2019131892A1 (en) * | 2017-12-27 | 2019-07-04 | ロート製薬株式会社 | External composition containing ascorbic acid and/or salt thereof |
| WO2020004194A1 (en) * | 2018-06-28 | 2020-01-02 | 小林製薬株式会社 | External-use composition |
| JP2020002060A (en) * | 2018-06-28 | 2020-01-09 | 小林製薬株式会社 | External composition |
| JP7321680B2 (en) | 2018-06-28 | 2023-08-07 | 小林製薬株式会社 | external composition |
| WO2020067132A1 (en) * | 2018-09-25 | 2020-04-02 | ロート製薬株式会社 | Topical composition containing ascorbic acid and/or salt thereof |
| JP2022183993A (en) * | 2021-05-31 | 2022-12-13 | ホーユー株式会社 | Composition for improving or repairing skin barrier function |
| JP7265278B2 (en) | 2021-05-31 | 2023-04-26 | ホーユー株式会社 | COMPOSITION FOR IMPROVING SKIN BARRIER FUNCTION OR REPAIR |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018162322A (en) | 2018-10-18 |
| JP2020117550A (en) | 2020-08-06 |
| JP7320581B2 (en) | 2023-08-03 |
| JP2022010339A (en) | 2022-01-14 |
| JP5951173B2 (en) | 2016-07-13 |
| JP7096285B2 (en) | 2022-07-05 |
| JP2015120766A (en) | 2015-07-02 |
| JP2016169240A (en) | 2016-09-23 |
| JP2017141304A (en) | 2017-08-17 |
| JP6152202B2 (en) | 2017-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6152202B2 (en) | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof | |
| JP5876962B2 (en) | Composition for external use | |
| JP6148454B2 (en) | Composition for external and internal use containing tranexamic acid | |
| WO2008047680A1 (en) | External preparation for skin | |
| JP2016020379A (en) | Photoaging inhibitor and inhibitor for skin thinning | |
| JP2016130224A (en) | External composition | |
| JPWO2020111067A1 (en) | Composition containing ether of fatty alcohol and glycerin | |
| JP2013170124A (en) | Azelaic acid-containing composition for external use | |
| JP6765299B2 (en) | Aqueous formulation | |
| JP2023166571A (en) | External composition | |
| JP7321680B2 (en) | external composition | |
| JP2019006737A (en) | Pharmaceutical composition | |
| JP2015218135A (en) | External preparation for skin | |
| JP5144153B2 (en) | Topical skin preparation | |
| JP7321679B2 (en) | external composition | |
| JP2017186329A (en) | Skin pigmentation inhibitor | |
| JP7153429B2 (en) | Active oxygen scavenging agent | |
| JP5902410B2 (en) | Composition for external use | |
| JP2021161037A (en) | Pharmaceutical composition for external use | |
| TW201622712A (en) | Pharmaceutical composition for external use | |
| JP2013056929A (en) | External preparation for skin | |
| JP7198573B2 (en) | Aqueous formulation | |
| JP2017095362A (en) | Liranaftate-containing external composition | |
| JP7102107B2 (en) | Aqueous preparation | |
| TW202228661A (en) | Topical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140225 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20140317 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140415 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150402 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150413 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20150515 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160608 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5951173 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |